Cutler Group LP Atea Pharmaceuticals, Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$3.0 - $4.97 $900 - $1,491	-300 Reduced 11.11%	2,400 $8,000
Q2 2022 Aug 04, 2022	SELL	$5.33 - $8.18 $23,089 - $35,435	-4,332 Reduced 61.6%	2,700 $19,000
Q1 2022 Apr 14, 2022	SELL	$5.5 - $9.19 $3,195 - $5,339	-581 Reduced 7.63%	7,032 $50,000
Q4 2021 Jan 18, 2022	BUY	$7.67 - $44.59 $25,027 - $145,497	3,263 Added 75.01%	7,613 $68,000
Q3 2021 Oct 26, 2021	BUY	$21.33 - $35.06 $60,790 - $99,921	2,850 Added 190.0%	4,350 $152,000
Q2 2021 Jul 19, 2021	BUY	$19.22 - $59.08 $28,830 - $88,620	1,500 New	1,500 $32,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.